A Brief Guide To Taxotere Lawsuits

French drug manufacturer Sanofi Aventis has been under fire as of late in relation to its chemotherapy drug Taxotere. The company has been the subject of lawsuits from breast cancer patients for not warning them of a serious side effect of the drug—permanent alopecia. Although hair loss is one of the common side effects of chemotherapy, taxotere has reportedly resulted to permanent hair loss.

The serious side effects of taxotere had not been known until December 2015 when the FDA has issued a warning on its label for its possible adverse reactions. Before that time, taxotere was the most popular drug used in chemotherapy. According to the website of Williams Kherkher, approximately 10 – 15% of women who used taxotere during treatment reported no hair growth for as long as ten years after stopping treatment.

Sanofi Aventis made around $1.4 billion per year for selling Taxotere. However, it was made at the expense of cancer patients who depended on the drug for survival and a possible chance of prolonging their life. Most of the lawsuits centered around Sanofi’s failure to determine the safety of Taxotere and its failure to warn patients of the risks associated with Taxotere. The plaintiffs also claimed that Sanofi misled them by saying that their hair will grow back but it did not. According to the plaintiffs, if they had known of the risks, they would have used other drugs for their treatment.

Taxotere can have serious consequences on a cancer patient. It could affect them emotionally and financially as well. If not for the drug, the patient would still have been earning much for their family. The good news is that there is still hope and those who have suffered may be able to recover damages and make the responsible parties liable for what they have done.

Taxotere lawsuits are covered by statute of limitations depending on the state so you must file the case within the time frame for filing a lawsuit.


Leave a Reply

Your email address will not be published. Required fields are marked *